Table 1.
Baseline euthyroid participant’s characteristics
| Variables | FHN Daily Trial N=147 |
FHN Nocturnal Trial N=48 |
P |
|---|---|---|---|
| Age (years) | 50.9 ± 14.1 | 53.8 ± 13.8 | 0.21 |
| Female | 48 (33%) | 18 (38%) | 0.54 |
| Diabetes Mellitus | 62 (42%) | 27 (56%) | 0.09 |
| Years since ESRD (Vintage) | <0.001 | ||
| < 2 years | 47 (32%) | 31 (65%) | |
| >= 2 years | 100 (68%) | 17 (35%) | |
| Body Mass Index (kg/m2) | 0.40 | ||
| < 18.5 | 7 (5%) | 2 (4%) | |
| 18.5–24.9 | 55 (37%) | 13 (27%) | |
| >= 25.0 | 85 (58%) | 33 (69%) | |
| Percent Body Fat (%) | 42.0 ± 8.63 | 43.7 ± 7.87 | 0.25 |
| ICW/kg | 0.27 ± 0.06 | 0.26 ± 0.07 | 0.35 |
| enPCR (g/kg/d) | 1.03 ± 0.26 | 0.95 ± 0.23 | 0.05 |
| HCO3− (Bicarbonate) (mMol/L) | 23.5 ± 3.55 | 21.9 ± 3.79 | 0.007 |
| FT3 (pg/mL) | 2.52 ± 0.80 | 2.71 ± 1.08 | 0.21 |
| FT4 (ng/dL) | 0.89 ± 0.24 | 0.94 ± 0.21 | 0.20 |
Abbreviations include: FHN, Frequent Hemodialysis Network; ESRD, end stage renal disease; ICW, intracellular water; enPCR, equilibrated normalized protein catabolic rate; FT3, free 3,5,3′-triiodo-L-thyronine; FT4, free thyroxine.